Faecal microbial transplantation (FMT) was pioneered as a licenced medicine by Professor Hawkey and his team at the University of Birmingham
An innovative treatment for patients with Clostridium difficile infection (CDI) which uses transplanted gut bacteria to treat the infection, is a more effective and more cost-efficient treatment than using antibiotics, a new UK study has found.
CDI is an infection of the bowel, which commonly affects people who have recently been treated in hospital, those with underlying conditions and patients over 65. Almost 30 per cent of patients treated for the condition experience at least one recurrence. A recurrence of the condition, has been associated with a higher risk of mortality and is usually treated using antibiotics.
Faecal microbial transplantation (FMT), a treatment pioneered as a licenced medicine by Professor Peter Hawkey and his team at the University of Birmingham, is a method where gut bacteria and other components in faeces are used to treat CDI. The bacteria is taken from a screened healthy donor, processed and screened before being transplanted via a tube passed through the nose into the stomach. Treatment with FMT is associated with higher cure and lower recurrence rates than fidaxomicin or vancomycin- the two most common antibiotics used to treat recurrent CDI (rCDI).
The study, which presents the first decision model for patients with rCDI already hospitalised in the UK, analysed randomised controlled trials, observational studies and expert opinion from the UK, on patients with single or multiple rCDI. Researchers analysed the cost of each of the four treatment options for rCDI for treatment effects, unit costs, resource and health related quality of life to identify which treatment was the most cost-effective and offered the best outcome for patients.
The study showed that both methods for administering FMT were lower in cost compared to standard treatment with antibiotics. FMT via naso-gastric tube was the least costly, with a mean cost of £8,877 per patient, while FMT via colonoscopy was £11,716 per patient. FMT via colonoscopy was also shown to be slightly more effective than treatment via naso-gastric tube, offering patients a higher quality of life. Two other standard antibiotic treatments vancomycin and fidaxomicin were compared in the model but both these treatments were shown to be more costly and less effective than either of the FMT interventions. Moreover, Vancomycin was the most expensive and the least effective treatment.
Professor Peter Hawkey, formerly of the University of Birmingham said, “We at the University of Birmingham pioneered this treatment as the UK’s first third party FMT service. FMT is not currently a widespread treatment for this disease but by showing that it not only saves lives, but is also significantly more cost effective, we hope that this could be one of the first steps towards the treatment being accepted more widely.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Clostridium difficile infection
- NHS review into hospital infections as figures show picture across North Weston February 25, 2021 at 5:06 am
NHS bosses are looking in to deaths from covid infections caught within North West hospitals after data suggested the region is disproportionately affected. Almost a third of covid patients in Arrowe ...
- Penn Scientists Discover Microbial Transplants Require Key T Cells for Successon February 20, 2021 at 4:15 pm
PHILADELPHIA: Scientists have known for more than a decade that “good bacteria” from healthy intestines can treat and ward off potentially deadly intestinal infections by Clostridium difficile ...
- C-diff cases highest in east of Englandon February 17, 2021 at 10:04 pm
THE number of superbug C-diff cases recorded in Suffolk is the highest in the east of England. Despite a dramatic fall in cases in the last year, the county's primary care trust, NHS Suffolk, still ...
- Antibiotic could be repurposed and added to tuberculosis treatment arsenalon February 17, 2021 at 9:51 am
Research has found fidaxomicin, an antibiotic usually used to treat bowel infections, prevents growth of resistant strains of Mycobacterium tuberculosis (MTb) in the lab.
- Clostridium Difficile News and Researchon February 9, 2021 at 4:01 pm
Could number two be number one when it comes to combating recurrent Clostridium difficile (CDI) infections?Using genetic material analysis and machine learning, UBC researchers have pinpointed ...
Go deeper with Google Headlines on:
Clostridium difficile infection
Go deeper with Bing News on:
Faecal microbial transplantation
- A healthy gut can improve blood cancer results, says studyon February 12, 2021 at 3:49 am
Blood cancer is one of the most common types of cancer that can affect anyone. According to the World Health Organization, India is the third-highest number of blood cancer cases. Also known as ...
- Scientists reveal mechanism behind fecal microbiota transplantationon February 10, 2021 at 12:51 pm
Fecal microbiota transplantation (FMT) is considered an effective alternative therapy as it addresses the issue from the ground up by replacing the damaged microflora with a healthy one through a ...
- Cross-species comparisons of host genetic associations with the microbiomeon February 2, 2021 at 4:00 pm
These authors contributed equally to this work. See allHide authors and affiliations Recent studies in human populations and mouse models reveal notable congruences in gut microbial taxa whose ...
- Why gut bacteria are becoming key suspects in autoimmune diseaseson February 2, 2021 at 4:02 am
"It's very frustrating that we have no therapy but liver transplantation," said Dr ... One suggestion for the cause is a leakage of microbial metabolites into the bloodstream, which goes straight ...
- Dysbiosis of gut microbiota in Polish patients with ulcerative colitis: a pilot studyon January 25, 2021 at 4:59 am
In the Polish population gut microbial composition has been ... in the development of effective targeted therapy, as faecal microbiota transplantation (FMT) has recently promised to be 33.